Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Performance Study of the Thermodiag Solution for Body Temperature Measurement

NCT06703931 · tracked via the Priya Life Science France tracker
Sponsor
F2D Medical
Phase
Not applicable
Started
2024-11-26
Last updated
2024-11-25

Condition(s) studied

Temperature Change, BodyEmergency Department Visit

Investigational drug(s) / intervention(s)

Measures performed on all subjects

Measures performed on all subjects: In intensive care Medics will use a reference medical device and Thermodiag®. Simultaneous and synchronised measurements will be taken every minute.

Study summary

The goal of this prospective, comparative, multi-centre interventional clinical investigation, is to evaluate the performance of the Thermodiag® medical device, compared with reference methods, for continuous measurement of core temperature in critical care patients. The main question it aims to answer is to develop non-invasive alternatives to the current methods of measuring core body, to reduce health risks, and overcome various other limitations (as infection, bleeding, thrombosis and local reactions).

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Patients aged 18 to 80 years; * Female or male patients; * Patients hospitalised in a critical care unit as defined by the Public Health Code of the Republic of France, Article R6123-33: 'The critical care activity consists of the care of patients who present or are likely to present one or more acute failures directly threatening the vital or functional prognosis and which may require recourse to one or more methods of substitution'. * Patients affiliated to the social security system or beneficiaries of such a system, where applicable, in accordance with local regulations; * Voluntary patients - or trusted person/family member/relative who have given oral and written consent after being informed by the investigator of the research. Exclusion Criteria: * Patients with a corpulence or physical characteristics responsible for a 'tourniquet' effect: arm circumference greater than 47 centimetres; * Patients with burns on the arm (location for Thermodiag® measurement); * Patients with particularly sensitive or affected skin in the biceps or armpit (left and right); * Patients undergoing an MRI examination; * Patients undergoing extracorporeal circulation; * Patients with a history of allergy to silicone; * Patients with active implantable medical devices such as pacemakers, defibrillators, etc. ; * Patients undergoing dialysis; * Patients with a tattoo in the area where the investigational device will be worn (arm); * Patients currently excluded from another protocol or taking part in another interventional research study; * Pregnant or breast-feeding women.

Primary outcome measure(s)

  • Body temperature Measurement — Every minute from the enrollment to the end of medical treatment (estimated time : 8 days)
    The degree of agreement between the two medical devices (Thermodiag® versus reference method in the hospital unit) will be assessed (expected measure is less than 0.1°C).

Trial sites (4)

FacilityCityRegionStatus
Centre Hospitalier De Fleyriat Bourg-en-Bresse France
Centre Hospitalier Intercommunal - Nord-Ardennes Charleville-Mézières France
Hôpital Privé de l'Ouest Parisien Trappes France
Hôpital Nord Franche-Comté Trévenans France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06703931 on ClinicalTrials.gov ↗ ← All trials in France